HomeNTLA • NASDAQ
Intellia Therapeutics Inc
$27.51
After Hours:
$27.48
(0.11%)-0.030
Closed: Mar 28, 4:12:09 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$27.02
Day range
$26.61 - $28.23
Year range
$22.67 - $47.48
Market cap
2.64B USD
Avg Volume
1.72M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
-1.92M-114.12%
Operating expense
28.99M22.72%
Net income
-132.16M-16.54%
Net profit margin
6.89K925.12%
Earnings per share
-1.46-5.80%
EBITDA
-137.43M-27.18%
Effective tax rate
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
912.22M-23.51%
Total assets
1.30B-14.42%
Total liabilities
250.81M-11.85%
Total equity
1.05B
Shares outstanding
96.11M
Price to book
2.39
Return on assets
-27.49%
Return on capital
-30.13%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-132.16M-16.54%
Cash from operations
-93.05M-3.54%
Cash from investing
45.94M252.36%
Cash from financing
106.48M-78.95%
Net change in cash
59.37M-84.61%
Free cash flow
-77.12M76.37%
About
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Founded
2014
Employees
526
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu